Category : Search result: Intellia Therapeutics

CRISPR Therapy Hits Major Roadblock: Intellia Pauses Phase 3 Trial After Patient Suffers Severe Liver Reaction

CRISPR Therapy Paused After Patient Liver Reaction

In a significant setback for gene editing medicine, Intellia Therapeutics halts its Phase 3 ATTR trial following a serious liver adverse event in a patient receiving CRISPR-based treatment NZ-1.

Page 1 of 1